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Abstract This paper describes progress made by the
Design Space Task Team within the ISPE Product Quality
Lifecycle Implementation (PQLI) initiative. It is intended to
provide approaches to the rational development of Design
Space, as well as background on Design Space, its
historical origins and how it fits within the wider PQLI
initiative. The focus of this paper is on the technical
elements of Design Space development.
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Introduction
This paper outlines the steps and elements for determining a
Design Space for pharmaceutical products and how this
Design Space can be used by industry to assure quality
products, patient safety and product efficacy.
The general engineering and technical design processes
discussed here have been widely used by many types of
industries in addition to the pharmaceutical industry
(including aerospace, food, computer, civil and mechanical
engineering and medical devices) and the use of risk based
analyses to determine design constraints and then determine
appropriate controls is a foundational process to the
advancement of science and technology. Accordingly, it is
appropriate for the pharmaceutical industry to expand the
use of these practices.
The paper seeks to clearly define what Design Space is,
and provide some guidance as to how to achieve it. It also
discusses issues including the relationship with Proven
Acceptable Ranges (PARs).
ICH Q8 [1] defines Design Space as:
“…the multidimensional combination and interaction
of input variables (e.g., material attributes) and process
parameters that have been demonstrated to provide
assurance of quality”
There are many scientifically justifiable means towards
achieving a Design Space. The approach to any specific
project can harness any combination of tools, depending on
the specific technologies being evaluated, available litera-
ture, internal corporate experience, and comfort level.
Design Space, especially when linked with a structured
Control Strategy, and criticality assessment, has the potential
to change aspects of regulatory interactions, providing data
and context while continuing to provide a high level of
assurance for pharmaceutical quality and performance.
Use of the Design Space approach allows more
effective dialogue between industry and regulator during
the application review process. It allows the regulator to
more readily see the connection between Design Space,
criticality and Control Strategy. It serves industry by
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providing a structured and deliberate approach that is well
aligned with a risk and science based approach to product
development.
There will be a wide range of approaches to the analysis
and output for a specific product, but transparency and
clarity is necessary, to explain and justify the approach, and
provide the foundation for continuous improvement. Con-
siderations on how to effectively present the Design Space
are given later in this paper.
If performed and articulated well, Design Space together
with an appropriate Control Strategy will reduce and focus
end product testing, while increasing process performance
and robustness. There are inherent benefits for taking this
approach, although it should be noted that traditional
approaches continue to be completely acceptable.
Development resources may be required to achieve a
knowledge rich understanding of the process, but this
investment can be offset by certitude of scale-up, more
consistent manufacturing, and potential regulatory flexibility.
This paper describes progress made by the Design Space
Task Teamwithin the ISPE PQLI initiative - a global industry-
led three to five year initiative aimed at facilitating the
implementation of ICH Q8, Q9 [3], and ultimately Q10 [4]
guidance.
This should be regarded as work in progress and
comment and input from industry, regulators, and other
stakeholders is welcomed.
Developing a Design Space
Design Space is dynamic and begins at drug conceptuali-
zation and continues to evolve over the entire lifecycle of
the process. At the time of initial product commercialization,
the Design Space can be considered to represent the best
overall process understanding at the time. It continues to
evolve, not because of lack of initial development effort, but
as additional knowledge and information is generated
throughout the lifecycle of the product: a key element of
continuous improvement programs.
Design space is determined by an iterative process. The
process is not complete until successive iterations demon-
strate appropriate understanding of attributes needed to
assure the Pharmaceutical Target Product Profile. While
this may vary for specific product, for many pharmaceutical
presentations the profile needed will be widely understood,
at least at a high level. Understanding of clinical needs and
therapeutic index are important, for example, in determining
this profile. Fig. 1.
Design Space is linked to criticality through the results
of risk assessment, which differentiates between those
product attributes and process parameters that are critical
to product quality (with underlying assumption of patient
safety and efficacy, and determining Critical Quality
Attributes (CQAs) and Critical Process Parameters (CPPs)).
ICH Q9 provides an excellent framework for Quality
Risk Management, including risk assessment. It also refers
to existing tools such as HACCP (Hazard Analysis and
Critical Control Points), ‘Worst Outcomes Analysis’,
FMECA (Failure Mode Effects and Criticality Analysis)
[5], any of which can provide a framework or be adapted to
provide a process for risk assessment.
Design Space may include information regarding site,
equipment and scale of manufacture, depending on the
level of the process knowledge, and the sensitivity of
process performance on those aspects.
A representation of Design Space and its links to overall
product and process knowledge and normal operating
ranges is given in Fig. 2.
Critical Quality Attributes and Critical Process Parameters,
once identified and understood, will need to be controlled.
Suitable systems and management processes can ensure
disciplined implementation of and adherence to the design
intent of the process. The forthcoming ICH Q10, which
addresses Pharmaceutical Quality Management Systems, will
provide guidance on these aspects. This outlines expectations
for the Pharmaceutical Quality Systems, and how they can be
applied in the management of the Design Space, risk
assessment, and to ensure that quality standards are met over
the lifecycle of the product.
Desired product attributes
Biological performance
(direct or indirect 
measurement)
Necessary attributes of 
formulation process to 
achieve desired product 
attributes
Attributes of drug substance 
that enable desired 
formulation process to 
achieve desired attributes
Process design to achieve 
necessary chemical purity
Target Product Profile Drug Product Design Space
Drug Substance Design 
Space
Fig. 1 Developing a design space
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Procedure for Determining a Design Space
Design Space is initially determined during product
development through an iterative process. Initially, the
links of the process to the profile may be tenuous, as central
elements of safety margins, clinical dose range, and the like
are becoming understood in parallel with the early
conceptualization and development of the process. It is
not unreasonable, therefore, to take a phased approach,
taking advantage of new safety and clinical information to
enhance the strength of process-product linkages over time.
Examples of quality attributes related to clinical rele-
vance include:
& Biopharmaceutics Classification System (BCS) class
& Physical (stable polymorph) and chemical stability
& Dose level and impacts on processes
& Risks based on formulation and API unit operations
& Particle Size spec established in supportive of product
profile
The process flow for a Design Space determination
within the overall product and process development is
shown in Fig. 3. It is adapted from work by the EFPIA PAT
Working Group [6].
Using the Pharmaceutical Product Profile and prior
knowledge, a risk assessment is performed. The risk
assessment will result in identification of areas where there
is a confirmed risk and a need to mitigate or control, or
where additional work is needed for further understanding
if risk is present.
The ability to determine levels of risk will depend highly
on the ability to judge severity and probability of impact. A
risk assessment, therefore, is a disciplined and structured
approach that clearly shows what has been considered and
the outcome of those considerations, including, where
necessary, the need to do further work.
The Design Space is linked to criticality through the
results of a risk assessment, which determines those critical
quality attributes and critical process parameters that must
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• A region where quality 
product can be 
produced.
• Includes material 
attributes and process 
parameters
• Arrived at by iterative 













Fig. 2 Representation of design
space
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Space and the process by which it is arrived at inform
decisions on criticality, links functional relationships be-
tween Critical Quality Attributes (CQAs) and the Critical
Process Parameters (CPPs) that impact them, and should
include their linkage across unit operations. Proven accept-
able ranges (PARs) are embedded within the design space.
It is not necessary to include normal operating ranges in the
design space, as they have no impact on a product’s
Pharmaceutical Target Product Profile.
The Design Space may also contain operating ranges for
process parameters classified in an intermediate criticality
category used by some companies, and proposed for further
consideration by the paper Criticality in PQLI [7] in this
Volume of Journal of Pharmaceutical Innovation. Examples
may include parameters that are well controlled in relation
to the required boundaries and are of lower risk.
The example shows what was considered, and how each
attribute was ranked and scored (see Fig. 4). This in turn,
informed the experimental strategy that was needed to
provide the necessary understanding. Figure 5 shows a non-
quantitative example of risk assessment.
Tools for Developing Design Space
The selection of the correct tools for development of the
Design Space may be influenced by the maturity of the
underlying science. Where the underlying scientific principles
are well understood and developed, it is possible to
characterize a process by use of first principle, or mechanistic
models.Where such underlying scientific understanding is not
possible, scale-up correlations or empirical assessments may
be suitable.
There is no single tool or approach that is ideal for every
case, and there are specific considerations that can help
decide the best tool to use. The principles, assumptions or
axioms below may be applied to small and large molecules
alike, and to drug substance as well as formulation, but the
ability to use them may be limited by knowledge of
underlying scientific principles.
Axiom #1 If first principle relationships prove to be
adequately predictive of process performance, then use
them. Consequently, there is often an inherent benefit in
terms of physical significance.
The places in which first principles are typically encoun-
tered are in the thermodynamic and rate phenomena typically
associated with chemical processing (with analogous appli-
cations in other areas). For example, in chemical reactions, it
is often possible to determine kinetic order and rate constant.
With appropriate understanding, it is possible to prospec-
tively set reaction conditions to optimize desired outcome.
Similar concepts can apply in thermodynamics, especial-
ly in separations, where understanding of phase equilibria
and operation within a thermodynamically controlled enve-
lope are important to achieving the intent of the process. In
order to fully capitalize on the above first principle
knowledge, an understanding of heat and mass transfer
effects can provide direction where there may be sensitiv-
Drug Product Risk Assessment – ‘Cause & Effect 
Matrix’


































Fig. 4 Example risk assessment
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ities, and to engineer the process to drive the desired
outcome. Examples are given later.
Axiom #2 If process performance is found to be scale
sensitive, the sensitivity should if possible be designed out
of the process. Otherwise, conduct experiments to under-
stand the parameters that need to be controlled in order to
assure process performance. The ties to physical signifi-
cance may not be as strong as mechanistic understanding,
but causal relationships can be drawn.
These are usually the process elements for which scal-
ability is improved by changing reagent addition order, or
addition rate, or stoichiometry. Many of these decisions are
informed by aspects that are understood or judged to be
important based on a level of knowledge from Axiom #1, but
can also be informed by scale up correlations, rules-of-thumb,
or definition of pseudo-kinetic order (for chemical reactions).
An example of this is mixing in chemical reactions. Some
systems are sensitive to locally high reagent concentrations
(as might occur when in-vessel blending is insufficient),
while others are more controlled by micromixing. Blending
and micromixing are known to not respond to increasing
scale in the same way. In this case, specific studies would be
carried out to determine which factor of interest dominates
the process and use that to govern scale up.
Axiom #3 When considering interactions of multiple
variables that cannot be modelled simply, perform empirical
tests (e.g., Design of Experiments - DOE) to map out
appropriate operating ranges.
This approach is common in biologics and formulation,
since much of the underlying science has not progressed as
far as it has for synthetic molecules. It is also useful in
understanding how typical fluctuations around mean input
values (e.g., starting materials) can influence the final
product.
Axiom #4 Data is not knowledge, unless context is also
provided. The traditional regulatory model has been to
provide the data showing that the process has appropriate
controls established. In a Design Space the underlying
context would be necessary to show how the data was
coupled with other elements, and the assumptions made.
Axiom #5 Design Space is not necessarily the same as
Proven Acceptable Range (PAR).
A combination of PARs does not add up to a Design Space.
PARs based on univariate experimentation can, however,
provide some knowledge about the process. When PARs are
based on a multivariate assessment of the appropriate process
parameters, they are a subset of design space.
Presentation of the Design Space
The presentation of Design Space is highly important in a
regulated industry where trust and transparency over a
product’s life cycle are essential. While the Design Space
Task Team has spent the majority of its effort on developing
and documenting the scientific principles and approach, some





















example of risk assessment -
multivariate cause and effect
relationship
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“common sense” considerations on presentation are given
here.
The presentation of the Design Space should start with a
brief guide that explains the process that was used during
development to assess criticality, define the Design Space, and
identify acceptable Control Strategies. This serves two
purposes. Firstly, since there will be a wide range of





































































































































































































 Level (%) 
The Drug Product Design Space
Fig. 6 Visualization of drug product design space
Modeling from first principles
PAT used to understand the reaction mechanism
Chirality is set via asymmetric hydrogenation
Enantiomeric excess (ee) ~95% in reaction stream
Enantio-selectivity decreases with increasing reaction temperature 
Temperature is critical process parameter (CPP), Max. 65°C 
Balance kinetics and selectivity by operating at 50°C 
Control chirality by controlling process conditions
Case Study #1
Fig. 7 Case study: control of process conditions
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describe the overall planned process. Secondly, it is necessary
for the historical record of what was done, and to provide the
foundation for continuous improvement.
The goal is to define causality in sufficient detail,
without excessive extraneous data or effort. The intent is
to present a summary that allows easy understanding of the
key elements. Technical presentation of every raw data
point generated would obscure the logic that connects
design considerations and design constraints.
Terms used should be clearly defined, especially any that
have not been previously published or differ from widely
accepted definitions (such as those listed in ICH guidance
documents).
The process used for risk assessment should be described,
including iterations where appropriate. This includes the
identification of Critical Quality Attributes and their function-
al relationships with process parameters and other quality
attributes that may impact them. This may include a
discussion of how prior knowledge, experience and scientific
literature were used during the initial risk assessments.
The information should be filtered to ensure that the
data, analysis and presentation are relevant to the process
discussed in the filing. Where information comes from prior
knowledge or literature sources, sufficient context should
be provided to allow the reviewer to see the bridge between
prior knowledge and the current application. Relevance
filtering also will prevent a significant level of non critical
and extraneous information.
The link between risk assessments and the generation of
experimental plans and models used to identify the Critical
Process Parameters and their acceptable operating ranges
should also be discussed. This may include statements
regarding how the development process evolved to obtain
additional knowledge and information to obtain further
clarity on the criticality of attributes and parameters through
process optimization.
Case Study #2: Control of Drying
Drug substance isolated in monohydrate form from isopropanol (IPA) and water 
Monohydrate form is stable under drying conditions
Conditions thermodynamically favor removal of IPA
Azeotrope of 88% IPA at 40°C






Fig. 8 Case study: control of drying
Design Space for Drying
Graphical Description







Known edge of failure due to degradation
Regions of uncertainty17.5%
Trajectories describing the 
boundaries of the design space 
where product quality is assured
Fig. 9 Case study: design space for drying
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The Design Space Task Team has considered different
approaches to summarizing process knowledge in a
pictorial fashion. Columns containing summaries of the
knowledge obtained for each unit operation may be
combined into a single diagram that links information
across the entire manufacturing process. Multivariate
analysis, modelling and prior knowledge may all be used
to prepare the information presented.
Further information on these approaches may be found in
PQLIKeyTopics - Criticality, Design Space andControl Strategy
[2] in this Volume of Journal of Pharmaceutical Innovation.
An alternative presentation of Design Space that allows
easy visualization of process is shown in Fig. 6.
Case Studies
Examples from First Principles Modelling
The first case shows a molecule in which the final chemical
step was an asymmetric hydrogenation that controlled the
chirality of the product. A first principle model was
developed that enabled the optimization of kinetics, cycle
time and selectivity of the reaction (See Fig. 7).
The second case relates to a thermodynamic model for
residual solvent from drying. The model enabled the
regulatory test for residual solvent to be removed from the
drug substance process, relying instead on Karl Fischer
(KF) titration to measure residual water. It is not thermo-
dynamically possible under the drying conditions to have a
KF meeting the drying specification with concurrent
presence of a meaningful level of ispropanol (IPA). This
enabled the optimization of drying cycle time and still
maintained the robust production of the desired crystal form
and morphology (See Fig. 8).
An alternative depiction of design space, for a
different drying case study, is shown in Fig. 9. This
example is based on experimentation instead of thermody-
namic modelling.
Examples of Empirical Models
This example shows the use of Design of Experiment
(DOE) to derive Design Space is shown in Fig. 10.
Compiling the data from the experiments into a contour
plot format gives the impact of compression variables on
tablet properties (See Fig. 11).
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Future Work and Next Steps
Integrated examples demonstrating practical application of
Design Space, criticality, and Control Strategy are neces-
sary to further refine the concept. The following are
suggested as fruitful areas for specific further study and
clarification:
& Links between risk and criticality and resultant Design
Space and Control Strategy. As presented here, risk
management and criticality assessment form the initial
steps of the Design Space definition process
& The role of scale and equipment in determining Design
Space and Control Strategy
& Changes to Design Space. Since new knowledge or
risks will emerge throughout the product lifecycle, this
contributes to continuous improvement
& Application of Design Space principles and concepts to
biologics and legacy products
& The extent to which Design Space determination
includes analysis of critical and non-critical aspects,
and what is eventually regulated
& The role of prior knowledge, including literature and
internal technical developments captured in report form
or as part of prior submissions. Prior knowledge
involves many disciplines including biopharmacuetics,
material classification, kinetics, thermodynamics, and
experimental design techniques.
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Example of Overlay Plot to Identify Impact of





























Fig. 11 Case study: impact of
compression variables
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